The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease

Neuroscience Letters

Volumn 416, Issue 3, 2007, Pages 294-298

  Degirmenci, Bumin ^a   Yaman, Mehmet ^a   Haktanir, Alpay ^a   Albayrak, Ramazan ^a   Acar, Murat ^a   Caliskan, Gulderen ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

Apparent; Diffusion; Diffusion coefficient; Magnetic resonance imaging; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 33947586601     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.02.022     Document Type: Article

References (34)

1. Basma A.N., Morris E.J., Nicklas W.J., and Geller H.M. l-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J. Neurochem. 64 (1995) 825-832
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
3. Desagher S., Glowinski J., and Premont J. Astrocytes protects neurons from hydrogen peroxide toxicity. J. Neurosci. 14 (1996) 2553-2562
4. Fahn S. Controversies in the therapy of Parkinson's disease. Adv. Neurol. 69 (1996) 477-486
5. Fahn S., and Elton E.R. Unified Parkinson's Disease Rating Scale. In: Fahn S., Marsden C.D., Calne D., and Goldstein M. (Eds). Recent developments in Parkinson's Disease (1987), Macmillan Press, Florham Park, NJ 293-304
6. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K., and Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
7. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
8. Friedman J.H., Feinberg S.S., and Feldman R.G. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA 254 (1985) 2792-2795
9. Jennings D., Innis D., Seibyl J., and Marek K. [(123)I]beta-CIT SPECT assessment of progression in early and late Parkinson's disease. Neurology 56 Suppl. 3 (2000) A74
10. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
11. Kish S.J., Shannak K., Rajput A., Deck J.H., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 642-648
12. Lai C.T., and Yu P.H. Dopamine- and l-beta-3,4-dihydroxyphenylalanine hydrochloride (l-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53 (1997) 363-372
13. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat. Rev. Neurosci. 4 (2003) 469-480
14. Le Bihan D., Turner R., Douek P., and Patronas N. Diffusion MR imaging: clinical applications. AJR 159 (1992) 591-599
15. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., Oakes D., and Seibyl J. [123I] beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
16. Mascalchi M., Tessa C., Moretti M., Della Nave R., Boddi V., Martini S., Inzitari D., and Villari N. Whole brain apparent diffusion coefficient histogram: a new tool for evaluation of leukoaraiosis. J. Magn. Reson. Imaging 15 (2002) 144-148
17. Mena M.A., Casarejos M.J., Carazo A., Paino C.L., and Garcia de Yebenes J. Glia protect fetal midbrain dopamine neurons in culture from l-dOPA toxicity through multiple mechanisms. J. Neural. Transm. 104 (1997) 317-328
18. Mena M.A., Davila V., and Sulzer D. Neurotrophic effects of l-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J. Neurochem. 69 (1997) 1398-1408
19. Mena M.A., Pardo B., Casarejos M.J., Fahn S., and Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov. Disord. 7 (1992) 23-31
20. Morris C.M., and Edwardson J.A. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3 (1994) 277-282
21. Mytilineou C., Han S.K., and Cohen G. Toxic and protective effects of l-dopa on mesencephalic cell cultures. J. Neurochem. 61 (1993) 1470-1478
22. Mytilineou C., Walker R.H., JnoBaptiste R., and Olanow C.W. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304 (2003) 792-800
23. Olanow C.W., and Stocchi F. Why delaying levodopa is a good treatment strategy in early Parkinson's disease. Eur. J. Neurol. Suppl. 1 (2000) 3-8
24. Parkinson Study Group. Dopamine Transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
25. Paulus W., and Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50 (1991) 743-755
26. Riederer P., and Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural. Transm. 38 (1976) 277-301
27. Schocke M.F., Seppi K., Esterhammer R., Kremser C., Jaschke W., Poewe W., and Wenning G.K. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58 (2002) 575-580
28. Schocke M.F., Seppi K., Esterhammer R., Kremser C., Mair K.J., Czermak B.V., Jaschke W., Poewe W., and Wenning G.K. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 21 (2004) 1443-1451
29. Seppi K., and Schocke M.F. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative Parkinsonism. Curr. Opin. Neurol. 18 (2005) 370-375
30. Seppi K., Schocke M.F., Donnemiller E., Esterhammer R., Kremser C., Scherfler C., Diem A., Jaschke W., Wenning G.K., and Poewe W. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov. Disord. 19 (2004) 1438-1445
31. Seppi K., Schocke M.F., Esterhammer R., Kremser C., Brenneis C., Mueller J., Boesch S., Jaschke W., Poewe W., and Wenning G.K. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the Parkinson variant of multiple system atrophy. Neurology 60 (2003) 922-927
32. Seppi K., Schocke M.F., Mair K.J., Esterhammer R., Scherfler C., Geser F., Kremser C., Boesch S., Jaschke W., Poewe W., and Wenning G.K. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 31 (2006) 240-245
33. Woessner D.E. NMR spin-echo self diffusion measurements on fluids undergoing restricted diffusion. J. Phys. Chem. 67 (1963) 1365-1367
34. Yoshikawa K., Nakata Y., Yamada K., and Nakagawa M. Early pathological changes in the Parkinsonian brain demonstrated by diffusion tensor MRI. J. Neurol. Neurosurg. Psychiatry 75 (2004) 481-484